iHuman Institute, ShanghaiTech University, Shanghai 201210, China; Yunnan Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Molecular and Clinical Medicine, Kunming Medical University, Kunming 650500, China; National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Cell. 2018 Feb 8;172(4):719-730.e14. doi: 10.1016/j.cell.2018.01.001. Epub 2018 Feb 1.
Drugs frequently require interactions with multiple targets-via a process known as polypharmacology-to achieve their therapeutic actions. Currently, drugs targeting several serotonin receptors, including the 5-HT receptor, are useful for treating obesity, drug abuse, and schizophrenia. The competing challenges of developing selective 5-HT receptor ligands or creating drugs with a defined polypharmacological profile, especially aimed at G protein-coupled receptors (GPCRs), remain extremely difficult. Here, we solved two structures of the 5-HT receptor in complex with the highly promiscuous agonist ergotamine and the 5-HT receptor-selective inverse agonist ritanserin at resolutions of 3.0 Å and 2.7 Å, respectively. We analyzed their respective binding poses to provide mechanistic insights into their receptor recognition and opposing pharmacological actions. This study investigates the structural basis of polypharmacology at canonical GPCRs and illustrates how understanding characteristic patterns of ligand-receptor interaction and activation may ultimately facilitate drug design at multiple GPCRs.
药物通常需要通过多靶点相互作用(称为多药理学)来实现其治疗作用。目前,靶向多种血清素受体的药物,包括 5-HT 受体,可用于治疗肥胖症、药物滥用和精神分裂症。开发选择性 5-HT 受体配体或具有明确多药理学特征的药物(特别是针对 G 蛋白偶联受体 (GPCR))的竞争挑战仍然极其困难。在这里,我们分别以 3.0Å 和 2.7Å 的分辨率解决了与高度混杂激动剂麦角新碱和 5-HT 受体选择性反向激动剂 ritanerin 复合的 5-HT 受体的两个结构。我们分析了它们各自的结合构象,为它们的受体识别和相反的药理作用提供了机制见解。本研究调查了经典 GPCR 多药理学的结构基础,并说明了如何理解配体-受体相互作用和激活的特征模式可能最终有助于多个 GPCR 的药物设计。